An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.
A Prospective Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections.
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT01173068, this observational or N/A phase trial focuses on Urinary Tract Infections and remains ongoing. Sponsored by Merck Sharp & Dohme LLC, it has been updated 7 times since 2010, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jun 2022 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Jun 2022 [monthly]
Unknown Status
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Unknown Status NA
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- National University Hospital, Singapore
For direct contact, visit the study record on ClinicalTrials.gov .